Analysis of Large Deletions in BRCA1, BRCA2 and PALB2 Genes in Finnish Breast and Ovarian Cancer Families

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2008 May 27

PMID 18501021

Citations 21

Authors

Katri Pylkas

Hannele Erkko

Jenni Nikkila

Szilvia Solyom

Robert Winqvist

Affiliations

Soon will be listed here.

Abstract

Background: BRCA1 and BRCA2 are the two most important genes associated with familial breast and ovarian cancer susceptibility. In addition, PALB2 has recently been identified as a breast cancer susceptibility gene in several populations. Here we have evaluated whether large genomic rearrangement in these genes could explain some of Finnish breast and/or ovarian cancer families.

Methods: Altogether 61 index patients of Northern Finnish breast and/or ovarian cancer families were analyzed by Multiplex ligation-dependent probe amplification (MLPA) method in order to identify exon deletions and duplications in BRCA1, BRCA2 and PALB2. The families have been comprehensively screened for germline mutation in these genes by conventional methods of mutation analysis and were found negative.

Results: We identified one large deletion in BRCA1, deleting the most part of the gene (exon 1A-13) in one family with family history of ovarian cancer. No large genomic rearrangements were identified in either BRCA2 or PALB2.

Conclusion: In Finland, women eligible for BRCA1 or BRCA2 mutation screening, when found negative, could benefit from screening for large genomic rearrangements at least in BRCA1. On the contrary, the genomic rearrangements in PALB2 seem not to contribute to the hereditary breast cancer susceptibility.

Citing Articles

Mutations of , , and Genes in Breast Tumor Tissue: Relationship with the Effectiveness of Neoadjuvant Chemotherapy and Disease Prognosis.

Tsyganov M, Sorokovikova S, Lutzkaya E, Ibragimova M Genes (Basel). 2023; 14(8).

PMID: 37628606 PMC: 10454606. DOI: 10.3390/genes14081554.

Importance of multigene panel test in patients with consanguineous marriage and family history of breast cancer.

Ozmen V, Caglayan A, Yararbas K, Ordu C, Aktepe F, Ozmen T Oncol Lett. 2022; 23(4):118.

PMID: 35261632 PMC: 8855161. DOI: 10.3892/ol.2022.13238.

Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond and .

Samuel D, Diaz-Barbe A, Pinto A, Schlumbrecht M, George S Cells. 2022; 11(3).

PMID: 35159349 PMC: 8834207. DOI: 10.3390/cells11030539.

HER2-positive breast cancer in a germline gene large deletion carrier.

Uchida N, Takeshita M, Suda T, Matsui Y, Yoshida M Int Cancer Conf J. 2021; 10(3):181-185.

PMID: 34221828 PMC: 8206432. DOI: 10.1007/s13691-021-00481-3.

Characterisation of protein-truncating and missense variants in in 15 768 women from Malaysia and Singapore.

Ng P, Boonen R, Wijaya E, Chong C, Sharma M, Knaup S J Med Genet. 2021; 59(5):481-491.

PMID: 33811135 PMC: 9046754. DOI: 10.1136/jmedgenet-2020-107471.

References

Swensen J, Hoffman M, Skolnick M, Neuhausen S . Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family. Hum Mol Genet. 1997; 6(9):1513-7. DOI: 10.1093/hmg/6.9.1513. View

Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N . Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006; 22(6):719-729. DOI: 10.1016/j.molcel.2006.05.022. View

Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A . A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007; 446(7133):316-9. DOI: 10.1038/nature05609. View

Woodward A, Davis T, Silva A, Kirk J, Leary J . Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families. J Med Genet. 2005; 42(5):e31. PMC: 1736061. DOI: 10.1136/jmg.2004.027961. View

Montagna M, Palma M, Menin C, Agata S, De Nicolo A, Chieco-Bianchi L . Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. Hum Mol Genet. 2003; 12(9):1055-61. DOI: 10.1093/hmg/ddg120. View

Agata S, Dalla Palma M, Callegaro M, Scaini M, Menin C, Ghiotto C . Large genomic deletions inactivate the BRCA2 gene in breast cancer families. J Med Genet. 2005; 42(10):e64. PMC: 1735936. DOI: 10.1136/jmg.2005.032789. View

Foulkes W, Ghadirian P, Akbari M, Hamel N, Giroux S, Sabbaghian N . Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res. 2007; 9(6):R83. PMC: 2246183. DOI: 10.1186/bcr1828. View

Sarantaus L, Huusko P, Eerola H, Launonen V, Vehmanen P, Rapakko K . Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur J Hum Genet. 2000; 8(10):757-63. DOI: 10.1038/sj.ejhg.5200529. View

Karhu R, Laurila E, Kallioniemi A, Syrjakoski K . Large genomic BRCA2 rearrangements and male breast cancer. Cancer Detect Prev. 2006; 30(6):530-4. DOI: 10.1016/j.cdp.2006.10.002. View

10.

Pylkas K, Tommiska J, Syrjakoski K, Kere J, Gatei M, Waddell N . Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. Carcinogenesis. 2006; 28(5):1040-5. DOI: 10.1093/carcin/bgl237. View

11.

Puget N, Gad S, Sinilnikova O, Stoppa-Lyonnet D, Lenoir G, Mazoyer S . Distinct BRCA1 rearrangements involving the BRCA1 pseudogene suggest the existence of a recombination hot spot. Am J Hum Genet. 2002; 70(4):858-65. PMC: 379114. DOI: 10.1086/339434. View

12.

Laurila E, Syrjakoski K, Holli K, Kallioniemi A, Karhu R . Search for large genomic alterations of the BRCA1 gene in a Finnish population. Cancer Genet Cytogenet. 2005; 163(1):57-61. DOI: 10.1016/j.cancergencyto.2005.05.014. View

13.

Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho J, Hamel N, Li G . Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A. 2007; 104(16):6788-93. PMC: 1871863. DOI: 10.1073/pnas.0701724104. View

14.

Vehmanen P, Friedman L, Eerola H, McClure M, Ward B, Sarantaus L . Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet. 1998; 6(13):2309-15. DOI: 10.1093/hmg/6.13.2309. View

15.

Garcia M, Fernandez V, Osorio A, Barroso A, Llort G, Lazaro C . Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat. 2008; 113(3):545-51. DOI: 10.1007/s10549-008-9945-0. View

16.

Xu C, Chambers J, Solomon E . Complex regulation of the BRCA1 gene. J Biol Chem. 1997; 272(34):20994-7. DOI: 10.1074/jbc.272.34.20994. View

17.

Huusko P, Paakkonen K, Launonen V, Poyhonen M, Blanco G, Kauppila A . Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am J Hum Genet. 1998; 62(6):1544-8. PMC: 1377159. DOI: 10.1086/301880. View

18.

Gad S, Bieche I, Barrois M, Casilli F, Pages-Berhouet S, Dehainault C . Characterisation of a 161 kb deletion extending from the NBR1 to the BRCA1 genes in a French breast-ovarian cancer family. Hum Mutat. 2004; 21(6):654. DOI: 10.1002/humu.9148. View

19.

Casilli F, Tournier I, Sinilnikova O, Coulet F, Soubrier F, Houdayer C . The contribution of germline rearrangements to the spectrum of BRCA2 mutations. J Med Genet. 2006; 43(9):e49. PMC: 2564582. DOI: 10.1136/jmg.2005.040212. View

20.

Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A . PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007; 39(2):165-7. PMC: 2871593. DOI: 10.1038/ng1959. View